Author + information
- Received April 20, 2018
- Accepted April 24, 2018
- Published online June 4, 2018.
- Michael V. McConnell, MD, MSEEa,b,∗ (, )@StopHeartDz@leftbundle@HeartBobH@StanfordMed@euanashley,
- Mintu P. Turakhia, MD, MASa,
- Robert A. Harrington, MDa,
- Abby C. King, PhDc and
- Euan A. Ashley, MBChB, DPhila
- aDivision of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California
- bVerily Life Sciences, San Francisco, California
- cDepartment of Health Research and Policy and Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, California
- ↵∗Address for correspondence:
Dr. Michael V. McConnell, Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Suite H2157, Stanford, California 94305-5233.
The growing recognition that “health” takes place outside of the hospital and clinic, plus recent advances in mobile and wearable devices, have propelled the field of mobile health (mHealth). Cardiovascular disease and prevention are major opportunities for mHealth, as mobile devices can monitor key physiological signals (e.g., physical activity, heart rate and rhythm) for promoting healthy behaviors, detecting disease, and aid in ongoing care. In this review, the authors provide an update on cardiovascular mHealth by highlighting recent progress and challenges with mobile and wearable devices for assessing and promoting physical activity and fitness, and for monitoring heart rate and rhythm for the detection and management of atrial fibrillation.
Dr. McConnell is an employee of Verily Life Sciences. Dr. Turakhia has received research support from Amazon, AstraZeneca, Bristol-Myers Squibb, Medtronic, the AHA, Apple, Janssen, Cardiva Medical, and Boehringer Ingelheim; holds equity in iBeat, AliveCor, Metrica Health, Zipline Medical, and CyberHeart; and has received consulting fees from Abbott, Medtronic, iRhythm, Precision Health and Boehringer Ingelheim; and has received honoraria for presentations from Medscape. Dr. Harrington has a research relationship with Apple (Apple Watch Study); has received consulting fees from Amgen, Bayer, Gilead, Merck, MyoKardia, and The Medicines Company; has received fees for consulting and educational programs from WebMD; has received grant funding from AstraZeneca, Bristol-Myers Squibb, CSL Limited, GlaxoSmithKline, Janssen, Merck, Novartis, Portola, Sanofi, and The Medicines Company; holds equity in Element Science and Scanadu; and holds an unpaid seat on the board of directors of the AHA. Dr. Ashley is founder of Personalis Inc. and Deepcell Inc; and is an advisor to Genome Medical and SequenceBio. Dr. King has reported that she has no relationships relevant to the contents of this paper to disclose.
- Received April 20, 2018.
- Accepted April 24, 2018.
- 2018 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.